28 Wilhelm SM, Carter C, Tang L *et al.* BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. *Cancer Res* 2004; **64**: 7099–109.
29 Mendel DB, Laird AD, Xin X *et al.* *In vivo* antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. *Clin Cancer Res* 2003; **9**: 327–37.
30 Faivre SJ, Raymond E, Douillard JBE *et al.* Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). *J Clin Oncol* 2007; **25** (18S): 3546.
31 Wood JM, Bold G, Buchdunger E *et al.* PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. *Cancer Res* 2000; **60**: 2178–89.
32 Liu Y, Poon RT, Li Q, Kok TW, Lau C, Fan ST. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. *Cancer Res* 2005; **65**: 3691–9.
33 Koch I, Baron A, Roberts S *et al.* Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics of PTK787/ZK 222584 in patients with unresectable hepatocellular carcinoma (HCC). *J Clin Oncol* 2005; **23** (16S): 4134.
34 Wedge SR, Kendrew J, Hennequin LF *et al.* AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. *Cancer Res* 2005; **65**: 4389–400.
35 Alberts SR, Morlan BW, Kim GP *et al.* NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)-interim review of toxicity. 2007 Gastrointestinal Cancer Symposium; 19–21 Jan 2007, Orlando, FL, USA. Abstract 186.
36 Laird AD, Vajkoczy P, Shawver LK *et al.* SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. *Cancer Res* 2000; **60**: 4152–60.
37 Kanai F, Yoshida H, Teratani T *et al.* New feasibility study design with hepatocellular carcinoma: A phase I/II study of TSU-68, an oral angiogenesis inhibitor. *J Clin Oncol* 2006; **24** (18S): 4145.
38 Hurwitz H, Fehrenbacher L, Novotny W *et al.* Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2004; **350**: 2335–42.
39 Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. *Science* 2005; **307**: 58–62.
40 Schwartz JD, Schwartz M, Lehrer D *et al.* Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. *J Clin Oncol* 2006; **24** (18S): 4144.
41 Malka D, Dromain C, Farace F *et al.* Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring. *J Clin Oncol* 2007; **25** (18S): 4570.
42 Zhu AX, Blaszkowsky LS, Ryan DP *et al.* Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. *J Clin Oncol* 2006; **24**: 1898–903.
43 Normanno N, De Luca A, Bianco C *et al.* Epidermal growth factor receptor (EGFR) signaling in cancer. *Gene* 2006; **366**: 2–16.
44 Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. *Hepatology* 1998; **28**: 68–77.
45 Couzin J. Cancer drugs. Smart weapons prove tough to design. *Science* 2002; **298**: 522–5.
46 Paez JG, Jänne PA, Lee JC *et al.* EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004; **304**: 1497–5.
47 Lynch TJ, Bell DW, Sordella R *et al.* Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004; **350**: 2129–39.
48 O'Dwyer PJ, Giantonio BJ, Levy DE, Kauh JS, Fitzgerald DB, Benson AB III. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's Study E1203. *J Clin Oncol* 2006; **24** (18S): 4143.
49 Moyer JD, Barbacci EG, Iwata KK *et al.* Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. *Cancer Res* 1997; **57**: 4838–48.
50 Philip PA, Mahoney MR, Allmer C *et al.* Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. *J Clin Oncol* 2005; **23**: 6657–63.
51 Thomas MB, Chadha R, Glover K *et al.* Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. *Cancer* 2007; **110**: 1059–67.
52 Ramanathan RK, Belani CP, Singh DA *et al.* Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. *J Clin Oncol* 2006; **24** (18S): 4010.
53 Prewett M, Rockwell P, Rockwell RF *et al.* The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. *J Immunother Emphasis Tumor Immunol* 1996; **19**: 419–27.
54 Lièvre A, Bachet JB, Boige V *et al.* KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. *J Clin Oncol* 2008; **26**: 374–9.
55 Zhu AX, Stuart K, Blaszkowsky LS *et al.* Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. *Cancer* 2007; **110**: 581–589.
56 Gruenwald V, Wilkens L, Gebel M *et al.* A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: final results. *J Clin Oncol* 2007; **25** (18S): 4598.
57 Louafi S, Hebbar M, Rosmorduc O *et al.* Gemcitabine, oxaliplatin (GEMOX) and cetuximab for treatment of hepatocellular carcinoma (HCC): results of the phase II study ERGO. *J Clin Oncol* 2007; **25** (18S): 4594.
58 Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. *Mol Cancer Ther* 2007; **6**: 1–12.
59 Scharf JG, Braulke T. The role of the IGF axis in hepatocarcinogenesis. *Horm Metab Res* 2003; **35**: 685–93.
60 Tanaka S, Ito T, Wands JR. Neoplastic transformation induced by insulin receptor substrate-1 overexpression requires an interaction with Grb2 and Syp signaling molecules. *J Biol Chem* 1996; **271**: 14 610–16.
61 Tanaka S, Smidt EV, Mohr L, Sugimachi K, Wands JR. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. *Hepatology* 1997; **26**: 598–604.
62 Tanaka S, Wands JR. A carboxy-terminal truncated IRS-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype. *J Clin Invest* 1996; **98**: 2100–8.
63 Tanaka S, Wands JR. Insulin receptor substrate-1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor-β1 induced apoptosis. *Cancer Res* 1996; **56**: 3391–4.
64 Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin RTK activity in TNF-α- and obesity-induced insulin resistance. *Science* 1996; **271**: 665–8.
65 Feng Y, Zhu Z, Xiao X, Choudhry V, Barrett JC, Dimitrov DS. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. *Mol Cancer Ther* 2006; **5**: 114–20.
66 Burtrum D, Zhu Z, Lu D *et al.* A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth *in vivo*. *Cancer Res* 2003; **63**: 8912–21.
67 Garber K. IGF-1: old growth factor shines as new drug target. *J Natl Cancer Inst* 2005; **97**: 790–2.
68 Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoel MJ *et al.* Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. *Int J Cancer* 2006; **119**: 2557–66.
69 Pawson T. Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. *Cell* 2004; **116**: 191–203.
70 Macdonald JS, McCoy S, Whitehead RP *et al.* A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. *Invest New Drugs* 2005; **23**: 485–7.
71 Schagdarsurengin U, Wilkens L, Steinemann D *et al.* Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. *Oncogene* 2003; **22**: 1866–71.
72 Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. *Nat Rev Cancer* 2006; **6**: 674–87.
73 Luo J, Manning BD, Cantley LC. Targeting the PI3K–Akt pathway in human cancer: rationale and promise. *Cancer Cell* 2003; **4**: 257–62.
74 Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. *Trends Mol Med* 2007; **13**: 433–42.
75 Frost P, Shi Y, Hoang B, Lichtenstein A. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. *Oncogene* 2007; **26**: 2255–62.
76 Raymond E, Alexandre J, Faivre S *et al.* Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. *J Clin Oncol* 2004; **22**: 2336–47.
77 Beuvink I, Boulay A, Fumagalli S *et al.* The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. *Cell* 2005; **120**: 747–59.
78 Luo JL, Kamata H, Karin M. IKK/NF-κB signaling: balancing life and death – a new approach to cancer therapy. *J Clin Invest* 2005; **115**: 2625–32.
79 Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. *Cell* 2005; **121**: 977–90.
80 Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. *J Clin Oncol* 2005; **23**: 630–9.
81 Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. *Clin Cancer Res* 1999; **5**: 2638–45.

82 Hegewisch-Becker S, Sterneck M, Schubert U *et al.* Phase I/II trial of botrezomib in patients with unresectable hepatocellular carcinoma. *J Clin Oncol* 2004; **22** (15S): 4089.
83 Malumbres M, Barbacid M. Cell cycle kinases in cancer. *Curr Opin Genet Dev* 2007; **17**: 60–5.
84 Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. *Nat Rev Cancer* 2004; **4**: 927–36.
85 Lee CY, Andersen RO, Cabernard C *et al.* *Drosophila* Aurora-A kinase inhibits neuroblast self-renewal by regulating aPKC/Numb cortical polarity and spindle orientation. *Genes Dev* 2006; **20**: 3464–74.
86 Ruchaud S, Carmena M, Earnshaw WC. Chromosomal passengers: conducting cell division. *Nat Rev Mol Cell Biol* 2007; **8**: 798–812.
87 Tanaka S, Noguchi N, Ochiai T *et al.* Outcomes and recurrence of initially resection of hepatocellular carcinoma meeting Milan criteria: Rationale for partial hepatectomy as first strategy. *J Am Coll Surg* 2007; **204**: 1–6.
88 Tanaka S, Arii S, Yasen M *et al.* Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. *Br J Surg* 2008; **95**: 611–19.
89 Gadea BB, Ruderman JV. Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in *Xenopus* egg extracts. *Mol Biol Cell* 2005; **16**: 1305–18.
90 Hauf S, Cole RW, LaTerra S *et al.* The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore–microtubule attachment and in maintaining the spindle assembly checkpoint. *J Cell Biol* 2003; **161**: 281–94.
91 Harrington EA, Bebbington D, Moore J *et al.* VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth *in vivo*. *Nat Med* 2004; **10**: 262–7.
92 Soncini C, Carpinelli P, Gianellini L *et al.* PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. *Clin Cancer Res* 2006; **12**: 4080–9.
93 Hoar K, Chakravarty A, Rabino C *et al.* MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. *Mol Cell Biol* 2007; **27**: 4513–25.
94 Wilkinson RW, Odedra R, Heaton SP *et al.* AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. *Clin Cancer Res* 2007; **13**: 3682–8.
95 Girdler F, Gascoigne KE, Eyers PA *et al.* Validating Aurora B as an anti-cancer drug target. *J Cell Sci* 2006; **119**: 3664–75.
96 Vakifahmetoglu V, Olsson M, Zhivotovsky B. Death through a tragedy: mitotic catastrophe. *Cell Death Differ* 2008; **15**: 1153–62.

doi: 10.1111/j.1349-7006.2008.01006.x